Chemoinformaics analysis of 3,11-Tetradecadien-1-ol
| Molecular Weight | 210.361 | nRot | 10 |
| Heavy Atom Molecular Weight | 184.153 | nRig | 2 |
| Exact Molecular Weight | 210.198 | nRing | 0 |
| Solubility: LogS | -4.376 | nHRing | 0 |
| Solubility: LogP | 4.924 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 41 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 14 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 41.5186 |
| nHD | 1 | BPOL | 26.0834 |
| QED | 0.422 |
| Synth | 2.536 |
| Natural Product Likeliness | 1.572 |
| NR-PPAR-gamma | 0.299 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.837 |
| HIA | 0.005 |
| CACO-2 | -4.323 |
| MDCK | 0.0000198 |
| BBB | 0.564 |
| PPB | 0.959076 |
| VDSS | 2.193 |
| FU | 0.0366262 |
| CYP1A2-inh | 0.91 |
| CYP1A2-sub | 0.187 |
| CYP2c19-inh | 0.331 |
| CYP2c19-sub | 0.064 |
| CYP2c9-inh | 0.301 |
| CYP2c9-sub | 0.919 |
| CYP2d6-inh | 0.018 |
| CYP2d6-sub | 0.234 |
| CYP3a4-inh | 0.334 |
| CYP3a4-sub | 0.073 |
| CL | 10.032 |
| T12 | 0.466 |
| hERG | 0.028 |
| Ames | 0.01 |
| ROA | 0.008 |
| SkinSen | 0.964 |
| Carcinogencity | 0.158 |
| EI | 0.989 |
| Respiratory | 0.042 |
| NR-Aromatase | 0.165 |
| Antiviral | Yes |
| Prediction | 0.79991 |